Onconetix (ONCO) Revenue — Quarter Ended Jun 30, 2025
Revenue for the quarter increased slightly compared to the immediately preceding quarter. However, revenue declined sharply from the same quarter one year earlier.
Key takeaway
Quarter ended Jun 30, 2025 · FY2025 Q2
Revenue for the quarter increased slightly compared to the immediately preceding quarter. However, revenue declined sharply from the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$106.5K
Revenue reported for this quarter.
Quarter-over-quarter
+4.8%
Change from the immediately preceding quarter.
Year-over-year
-84.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$1.3M
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2024 | $406.9K | n/a |
| Dec 31, 2024 | $712K | n/a |
| Mar 31, 2025 | $101.6K | -85.5% |
| Jun 30, 2025 | $106.5K | -84.9% |
Revenue performance
The reported revenue direction is upward on a sequential basis, marking a modest improvement from the prior quarter's level.
Quarterly comparison
Compared with the immediately preceding quarter, revenue rose. Compared with the same quarter one year earlier, revenue fell substantially.
What to watch
The company's cash position and working capital deficit, as noted in the filing, raise substantial doubt about its ability to continue as a going concern.